Additional Coverage:
The Food and Drug Administration (FDA) is currently reviewing seven unapproved peptide substances that have gained significant attention for their potential health benefits. The agency’s Pharmacy Compounding Advisory Committee is scheduled to meet on July 23 and 24 at the FDA’s White Oak Campus in Silver Spring, Maryland, to discuss whether these peptides should be added to the 503A Bulks List. Inclusion on this list would permit their use in certain compounded prescription medications.
Despite lacking FDA approval, these peptides are widely accessible through wellness clinics, compounding pharmacies, and various online sellers operating in a regulatory gray area. The increased consumer interest spans applications such as weight loss, muscle building, performance enhancement, chronic disease management, and wound healing.
Notably, Health and Human Services Secretary Robert F. Kennedy Jr. has expressed support for expanding access to some peptide therapies. However, FDA reviewers have raised concerns regarding the limited clinical evidence available to confirm the safety and effectiveness of these substances.
The seven peptides under consideration have varied proposed uses and delivery methods:
- For ulcerative colitis: oral capsules, nasal sprays, injections, creams, and suppositories
- For wound healing: subcutaneous or intramuscular injections
- For wound healing and inflammatory conditions: topical creams and gels
- For obesity and osteoporosis: subcutaneous injections
- For cerebral ischemia, migraines, and facial pain: intranasal sprays and subcutaneous injections
- For opioid withdrawal, chronic insomnia, and narcolepsy: subcutaneous injections
- For insomnia: subcutaneous injections
Dr. Alex Tatem, a board-certified urologist and performance medicine expert, is expected to testify at the hearings.
He highlighted compounds such as BPC-157 and TB-500, which have demonstrated promising healing properties and a strong safety profile in multiple studies. Dr.
Tatem emphasized that millions of doses have been administered with very few reported adverse effects, attributing the safety to the peptides’ natural presence in the human body.
The FDA, however, maintains that more rigorous human clinical trials are necessary to fully assess the risks and benefits. The agency cautions that structural similarity to naturally occurring substances does not guarantee safety.
Dr. Marc Siegel, senior medical analyst for Fox News, echoed this sentiment, stressing the need for careful study and expressing concerns about potential kidney impacts.
While the committee’s recommendation will influence the FDA’s decision, the final determination will come after the agency completes its rulemaking process. Dr. Tatem expressed hope that, if approved, patients could soon access these therapies through prescriptions monitored by healthcare providers, including telehealth services.
He also encouraged the public to engage with their local representatives to advocate for regulated access to safe peptides produced domestically. As the FDA review proceeds, stakeholders await clarity on how these emerging therapies will be integrated into medical practice.